Health Care·Biotechnology·$109.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.13 | N/A | -32.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.13 | N/A | -32.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their drug development programs. They acknowledged the EPS shortfall but emphasized their commitment to future growth.
Management highlighted ongoing developments in their pipeline.
They expressed confidence in long-term growth despite the EPS miss.
Despite missing EPS expectations, Vertex Pharmaceuticals' stock rose by 4.56%, indicating investor optimism. The increase may be attributed to positive sentiment around their ongoing drug development efforts. Investors seem to be looking beyond the short-term EPS miss, focusing instead on the company's long-term potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PG&E CORP
Oct 29, 2012